|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 15, 2002; DOI 10.1182/blood-2002-04-1089.
HOW I TREAT
From the National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, MD.
Heparin-induced thrombocytopenia (HIT) is one of
the most common and potentially devastating of immune-mediated drug
reactions.1 The clinical manifestations of this disorder
are initiated by antibodies directed against platelet factor 4 (PF4),
which becomes an antigenic target when bound to heparin. The immune
complex binds to the Fc HIT should be suspected clinically in a patient who has received
heparin as recently as 5 days previously (or longer) and who has a
platelet count that has decreased to less than 150 000/µL (150 × 109/L minimal decrease of 30 000/µL
[30 × 109/L]) or has decreased by 50% or more below
baseline values.3 This time period can be reduced from 5 days to a matter of hours when heparin is initiated in a patient who
has previously received the drug in the past 120 days and has
circulating antibodies that bind to the heparin/PF4 complex.
The following sections discuss the duration of risk for HIT, the role
of assays in establishing the diagnosis, and the use of alternate
anticoagulants in specific clinical settings. Many unanswered questions
about HIT remain; however, with early recognition of HIT and initiation
of appropriate alternative anticoagulants that are now commercially
available, the morbidity and mortality associated with this disorder
can be significantly reduced.
Two different types of assays are generally available for the
detection of antibodies against PF4. The more sensitive assay is the
enzyme-linked immunosorbent assay (ELISA), in which antibodies are
detected immunologically; the functional test detects antibody that is
at a sufficient concentration to induce serotonin release from
activated platelets or to induce aggregation of platelets from a
healthy donor in the presence of patient sera and low
concentrations of heparin. The functional assay requires a sufficiently
high titer of antibodies to induce platelet activation and aggregation, whereas the ELISA, which usually is designed to detect antibodies of
the IgG, IgM, or IgA isotype, may detect antibodies that are too low in
titer to have clinical significance. Thus, the functional assay
correlates more closely with thrombocytopenia than does the antigenic
assay.3
Generally, HIT with thrombosis is most likely to occur in patients who
have inflammatory processes due to surgery or infection; the cytokine
release associated with these conditions lowers the threshold for
platelet activation, resulting in secretion of PF4. According to one
report, patients at relatively high risk for developing HIT and
thrombosis are those who have undergone orthopedic procedures.4 In this prospective study of postoperative
patients who received unfractionated porcine heparin for a period of 9 days, the percent developing antibodies to PF4 as assessed by the
antigen and functional assays was 14% and 9%, respectively; however,
only 5% of the patients developed thrombocytopenia.
Although several reports have described a relatively high frequency of
antibody formation in patients before cardiopulmonary bypass
procedures, the incidence of HIT after surgery appears to be quite
low.4-6 This may be due to the limited exposure of the
patient to heparin or it may also be an underestimation of the problem
because the duration of follow-up is relatively brief. For patients who
are undergoing cardiopulmonary bypass surgery, antibody is detected by
an ELISA method in approximately 20% preoperatively and in as many as
61% postoperatively.5,6 If a functional assay is used to
detect antibody, approximately 5% of patients test positive before
bypass surgery and 13% to 20% are positive in the postoperative
period.4,6 The antibodies detected before bypass
procedures are usually of the IgM isotype and may have developed after
other recent cardiac procedures. The antibody isotypes that are
detected after bypass surgery are IgG or IgM or both and are of lower
titer than those found in patients with thrombocytopenia. Although the
studies in which antibody formation was measured prospectively did not
report thrombosis in any of the patients, the study populations were
small and patients were not followed for prolonged periods of
time.5,6 Thus, individuals who have undergone
cardiopulmonary bypass procedures should be considered to be at risk
for thrombosis that may become evident after hospital discharge.
In a small prospective study of 54 patients undergoing vascular surgery
(carotid endarterectomy, aortic reconstruction, and infrainguinal
bypass), only 2 patients tested positive for antibodies (as assessed by
the ELISA procedure specific for IgG antibody) both before and after
the surgical procedure, and neither developed thrombosis.7
One additional patient converted from a negative test result before
surgery to a positive result after surgery, but remained asymptomatic.
Antibodies to the heparin/PF4 complex can persist in the circulation
for several months after the discontinuation of the drug. The duration
depends on the assays used for antibody detection. For example,
the median duration for patients with HIT to test positive for antibody
as assessed with a functional assay is 50 days (95% CI, 32-64 days);
by immunologic detection with the more sensitive ELISA, the median
duration is 85 days (95% CI, 64-124 days).3
Conceptually, the spectrum of HIT can be defined in 4 phases (Figure
1), with all 4 occurring simultaneously
in some patients and in others, never progressing beyond the first
phase. The first phase is the development of antibodies detected in an
ELISA followed by a second phase in which titers increase sufficiently
to be detected in a functional assay. The third phase is the decrease in the platelet count, which may progress to the fourth phase of
clinical thrombosis. With cessation of heparin and initiation of an
alternate anticoagulant, the platelets increase toward normal within
several days and the thrombosis resolves. However, the functional assay
may remain positive after resolution of the thrombosis and
thrombocytopenia; even after the functional assay becomes negative, the
more sensitive ELISA may continue to be positive for as long as 124 days.3
HIT with thrombosis can occur in patients from 5 to 19 days after
the cessation of heparin therapy.8 This may be due to the
presence of high titers of antibodies that can recognize PF4 in the
absence of heparin, or the antibodies may recognize PF4 that is bound
to glycosaminoglycans that are on the endothelial cell
surface.8 Another possibility is that subclinical
thrombosis may have occurred earlier and then gradually progressed to a
clinically evident process.
Patients who develop delayed HIT with thrombosis may have been exposed
to heparin during a previous recent hospitalization (eg, for coronary
artery bypass procedure) and discharged without any noticeable decrease
in platelet count. Between 5 and 19 days (or longer) after their last
exposure to heparin, they may present to the emergency department or to
their local physician with evidence of thrombosis. The platelet count
may be decreased or may be in the normal range but undergo a rapid
reduction within hours after initiation of heparin. Recognizing these
manifestations of HIT in such patients through taking a careful history
of previous hospitalization and exposure to heparin is essential,
because alternative anticoagulant agents would be indicated.
Another potential manifestation of HIT can develop in patients who have
had an exposure to heparin as long ago as 120 days.3 These
patients may have circulating antibodies that cause them to be at risk
for HIT when they are re-exposed to heparin for any reason (eg, heparin
prophylaxis for immobilization). In these patients, thrombocytopenia
may be seen within hours after initiation of heparin.
Past exposure to heparin appears not to induce an anamnestic
response.3 For 3 patients who received heparin beginning
10 months to 13.5 years after a previous documented episode of HIT, thrombocytopenia did not recur after initiation of heparin. In 4 patients who underwent vascular procedures after having had HIT as
recently as 1.5 months previously, thrombocytopenia did not recur.
These limited observations suggest that initiation of heparin in
patients with a previous history of HIT who no longer have antibodies
does not automatically reinduce antibody formation. Nonetheless, for
patients who have a history of HIT, unfractionated heparin could be
avoided for most clinical settings, with the exception of coronary
artery bypass surgery (see "An approach to HIT in coronary artery
bypass surgery"). In this latter situation, unfractionated heparin is
still the most easily used anticoagulant unless there is strong
rationale for using an alternative agent.
Low-molecular-weight (LMW) heparin cannot be used in patients with HIT
because of the high cross-reactivity of the antibody with the LMW
heparin/PF4 complex. However, LMW heparin can be used in a patient who
has a history of HIT but does not have evidence of circulating
antibodies. LMW heparin is much less likely than unfractionated heparin
to induce antibody formation. The pentasaccharide fondaparinux
(Arixtra) may have a role in the treatment of HIT because the drug
appears not to interact with PF4.
Several agents are now available as alternatives to heparin in
patients with suspected HIT; these are summarized in Table 1. They include the thrombin-specific
inhibitors lepirudin (Refludan; Hoechst Roussel, Kansas City, MO) and
argatroban (GlaxoSmithKline, Research Triangle Park, NC) as well as the
LMW heparinoid known as danaparoid sodium (Orgaran; Organon, West
Orange, NJ).
All of these agents require careful dosing because none has an antidote. Of these agents, danaparoid sodium is the agent that would be used in pregnant women. Ideally, a hospital that has an active surgery and cardiac service should have all 3 agents in the pharmacy because each has its specific strengths and disadvantages. All agents are discussed in the sections below, because in some situations, only one of these agents may be available or appropriate for the clinical setting. Lepirudin Lepirudin, which is a recombinant form of hirudin, is a 65-amino acid natural thrombin inhibitor. A meta-analysis of 2 prospective studies of patients with HIT and thromboembolic complications showed that initiation of lepirudin decreased the risk of the combined end point of death, new thromboembolic complications, and limb amputation from 6.1% per day before treatment to 1.3% per day during treatment.9 Historical controls were used as the comparison group. The efficacy and safety of lepirudin correlated with the degree of anticoagulation provided, as assessed by the activated partial thromboplastin time (aPTT) ratio (measurement of the patient aPTT divided by the median aPTT value of the normal laboratory range). aPTT ratios of 1.5 to 2.5 were associated with the highest efficacy. Lower ratios were subtherapeutic and higher ratios caused excessive bleeding. In patients with aPTT ratios of 1.5 to 2.5, the reduction in combined end points (relative risk [RR] = 0.42) was associated with only a moderate increase in risk for bleeding (RR = 3.2). Venous gangrene did not develop in any of the 93 patients who were switched to oral anticoagulation while receiving lepirudin. Covariates of sex, age (> 65 years), and patient population (medical versus surgical) did not affect patient outcome or bleeding risk.Current dosing recommendations are for 0.4 mg/kg as a bolus with 0.15 mg/kg/h (up to weight of 110 kg); the dose can be monitored with the aPTT. Lepirudin has a half-life of approximately 1.5 hours in healthy volunteers; this can be prolonged to 52 hours in patients with greatly reduced renal function,10 and dosing needs to be appropriately adjusted. The manufacturer recommends that dosing be reduced by 50% for both bolus and infusion for patients with a creatinine of 1.5 to 2.0 mg/dL. Reductions should be even greater for more severe renal impairment (see "HIT in dialysis patients"). Lepirudin should also be used cautiously in older individuals with small muscle mass, because relatively low serum creatinine values may cause an underestimation of the degree of renal impairment. A disadvantage of lepirudin is the tendency for some patients to develop antihirudin antibodies that enhance its anticoagulant activity. In one prospective study of patients receiving long-term lepirudin, antibodies were not detected until at least 6 days of treatment.11 As determined by ELISA methodology, 84% of patients receiving intravenous lepirudin developed antibodies, which were mainly detected between the 10th and 30th day of treatment. This study and an additional report12 found that in patients with antibodies, the aPTT tended to increase although the dose was not altered, leading the authors to speculate that recombinant hirudin antibodies prolong the half-life of the drug, perhaps by decreasing the rate of renal clearance of the hirudin that is in an immune complex. Thus, at least daily monitoring of the aPTT should be performed throughout the course of lepirudin administration to assess the need for dose reduction.11,12 Argatroban Argatroban, an arginine-based synthetic thrombin inhibitor, has been evaluated in a multicenter, nonrandomized, open-label trial of patients with HIT, which used as the composite end point the development of new thrombosis, all-cause death, or all-cause amputation. These combined events were significantly reduced in argatroban-treated patients compared to historical controls (25.6% versus 38.8%; P = .014).13 For those patients with HIT and thrombosis, the incidence was 43.8% versus 56.6% for the controls (P = .13). Bleeding events were similar between the 2 groups, but the argatroban-treated patients had a much more rapid increase in the platelet count and a significant reduction in new thrombosis and death caused by thrombosis. The treatment dose was 2 µg/kg/min; with this dose the aPTT was in therapeutic range (1.5-3 times baseline) within 4 to 5 hours of initiation of therapy.Argatroban has a half-life of 40 minutes in individuals with normal hepatic function.14 The clearance of argatroban in elderly men is approximately 20% lower than in elderly women.15 However, the dosing of argatroban is essentially not affected by age or sex. Argatroban is not excreted renally and therefore a dose reduction is not required in patients with renal insufficiency. Argatroban is cleared by the liver; when administered to patients with liver disease, argatroban has a 4-fold decrease in clearance and a 2-fold increase in elimination half-life when compared with values obtained in healthy volunteers. Thus, if argatroban is to be used in patients with compromised liver function, a 4-fold decrease in the starting dose would be recommended, with allowances of additional time beyond 1 to 3 hours for anticoagulant activity to achieve a steady state.15 Laboratory monitoring of the thrombin-specific inhibitors The thrombin-specific inhibitors, unlike unfractionated heparin, prolong the prothrombin time (PT) as well as the aPTT.16 However, the aPTT is the preferred test for monitoring the anticoagulant activity in clinical settings other than coronary artery bypass surgery and percutaneous coronary angioplasty (see "An approach to HIT in coronary artery bypass surgery" and "HIT in interventional cardiology"). The manufacturer for lepirudin recommends that the dose be adjusted to achieve a ratio of the patient aPTT to that of the laboratory reference value of 1.5 to 2.5. Lepirudin should not be initiated in patients who initially have an aPTT ratio of 2.5 or higher. Manufacturers of argatroban recommend maintaining the aPTT at 1.5 to 3 times the initial baseline value for the patient; however, the aPTT is not to exceed 100 seconds.More precise testing that directly reflects the levels of the thrombin inhibitors and that is not based on the aPTT has been developed and could be used as a replacement for the aPTT, especially for patients who may have a lupus anticoagulant. The quantitative thrombin time measures the clotting time of purified fibrinogen in the presence of a standard concentration of thrombin and diluted patient plasma.17 The prolongation of the clotting time is correlated with the concentration of thrombin-specific inhibitor in the patient plasma. This test is not commercially available. The ecarin clotting time can also be used as an alternate test. The principle of the test is that the snake venom ecarin activates prothrombin to meizothrombin independently of phospholipids or calcium.18,19 The hirudin inhibits meizothrombin and this is reflected in the clotting time. Thus, a standard amount of ecarin is added to whole blood or plasma and the clotting time is measured in the presence of hirudin. The degree of prolongation of the clotting time correlates with the concentration of hirudin. A device (Cardiovascular Diagnostics, Raleigh, NC) to monitor the ecarin clotting time for patients undergoing cardiopulmonary bypass surgery has been approved for compassionate use by the Food and Drug Administration (FDA). Danaparoid sodium Danaparoid sodium, which is prepared from animal intestinal mucosa, is composed of heparan sulfate, dermatan sulfate, and chondroitin sulfate.1 The original FDA-approved indication for danaparoid sodium was for prophylaxis against venous thromboembolism after surgery; however, it is used primarily as an immediate substitute for heparin in patients suspected of having HIT. Danaparoid sodium has an antifactor Xa/antifactor IIa activity of 28:1 (compared to a 1:1 ratio for heparin); the elimination half-life of the antifactor Xa activity is 24 hours and that of the minor component of antifactor IIa is approximately 4 hours.20 The steady state of antifactor Xa activity is reached after 4 to 5 days of dosing. Danaparoid sodium can be monitored by its antifactor Xa activity; however, the assay for the antifactor Xa activity should contain danaparoid sodium as the standard. Antifactor Xa levels should be measured in patients who have either low or high body weight (< 55 kg or > 90 kg), severe renal disease, or who are to have an invasive procedure (to ensure that the antifactor Xa activity is in an acceptably low range). Approximately 40% to 50% of the plasma clearance of danaparoid sodium is through the kidneys; patients who have renal insufficiency should therefore receive reduced doses after the initial dose has been administered. Danaparoid sodium cannot be neutralized by protamine sulfate.For prophylaxis against venous thromboembolism in patients with suspected HIT, a dose of 750 antifactor Xa units twice daily subcutaneously can be used. For treatment of active thrombosis in a patient with normal renal function, the dose can be increased to 1500 U intravenously as a bolus followed by 1500 U subcutaneously twice daily. This recommendation, which is a "middle ground," represents a simple doubling of the prophylactic dose. The support for this dose is based on a randomized study that showed that in patients with normal renal function who had venous thromboembolism, danaparoid sodium at a dose of 1250 U intravenous bolus followed by 1250 U twice daily subcutaneously was similar in efficacy to unfractionated heparin.21 Even greater efficacy was achieved with a higher dose. In a study of patients who did not have HIT, danaparoid sodium administered at a bolus of 2000 U intravenously followed by 2000 U subcutaneously twice daily was associated with a significantly lower risk of recurrence or extension of thrombosis compared to heparin (13% versus 28%; RR = 0.45; 95% CI, 0.21-0.90).21 Other dosing regimens for danaparoid sodium in the treatment of venous thromboembolism are to administer 2500 U intravenously (1250 U if weight is < 55 kg and 3750 U if > 90 kg) followed by 400 U/h for 4 hours, then 300 U/h for 4 hours and finally 150 to 200 U/h to maintain antifactor Xa activity at 0.5 to 0.8 U/mL.22
For the intensive care unit (ICU) setting, thrombin-specific inhibitors are ideal because they have short half-lives. Neither argatroban or lepirudin has an antidote that can provide immediate reversal of anticoagulation; their short half-lives are the best form of reversal. If severe bleeding were occurring in the presence of one of these agents, infusion of recombinant factor VIIa at a dose of 90 µg/kg could be considered. Danaparoid sodium can be administered to critically ill patients with HIT, although in one small series, approximately 6.5% of patients with HIT who received this drug had persistent thrombocytopenia, indicating possible cross-reactivity with the heparin-induced antibodies.23 Ideally, if danaparoid sodium is to be used at doses higher than those used for prophylaxis in the ICU setting, assays should be readily available for monitoring anticoagulation, and the lowest effective dose should be used to reduce the risk for bleeding. Furthermore, a minimum of 24 hours should be allowed between the last dose and a planned invasive procedure, and antifactor Xa levels should be measured prior to the procedure. If a patient with HIT who is receiving a thrombin-specific inhibitor is being transferred from the ICU and requires continued anticoagulation, then consideration can be given to changing to danaparoid sodium, which can be given subcutaneously and does not require monitoring. Because danaparoid sodium does not prolong the PT, it is an excellent bridging agent to use during the initiation of warfarin.
The ideal alternative to heparin for patients receiving dialysis is argatroban because it is not excreted by the kidneys and does not require dose adjustment in these patients.15,24 Although the half-life of lepirudin in patients undergoing renal dialysis is 52 hours, the drug has been used successfully to maintain anticoagulation during dialysis when given one time prior to dialysis at a dose of 0.08 mg/kg.25 For ICU patients receiving continuous venovenous hemodialysis, lepirudin has been infused at doses as low as 0.006 to 0.025 mg/kg/h or administered as repetitive doses (0.007-0.04 mg/kg).26 Danaparoid sodium has been used as a continuous infusion in patients undergoing hemofiltration; the initial bolus was 2500 U followed by a dose of 200 to 600 U/h.27 However, others have used 100 to 400 U/h (intravenously) to maintain the antifactor Xa activity between 0.5 and 1 U/mL.23 Danaparoid sodium has also been used at a dose of 3750 U for patients undergoing hemodialysis27; an alternative approach is to administer 40 U/kg intravenously.23
When reviewing the anticoagulant options for a patient who requires coronary artery bypass surgery and either has active HIT or a remote history of HIT, the physician must first decide if heparin can be used as the anticoagulant, because it is easily monitored and rapidly neutralized. Furthermore, experience with alternatives to heparin in the cardiopulmonary bypass setting is limited. If bypass can be delayed 3 to 4 weeks and if the platelet count has returned to normal, then heparin can probably be used successfully during surgery, followed by an alternative anticoagulant beginning in the postoperative period. If a bypass procedure is essential in a patient who has had HIT within the past 4 weeks, then danaparoid sodium or lepirudin could be considered, although both would be used "off label" for this indication. Argatroban is not recommended because the appropriate dose for bypass has not been established. If danaparoid sodium or lepirudin is to be used, the frequent monitoring of the anticoagulant should be carefully coordinated among the consulting services.28 Several reports describe the successful use of danaparoid sodium in the cardiopulmonary bypass setting. In some instances, bleeding has been excessive; however, this can be reduced by administering doses that maintain the antifactor Xa level at 0.7 to 1.5 U/mL and by using hemostatic agents such as fibrin sealant at the sternotomy site.29 The activated clotting time, which is based on the principle of using celite or kaolin to activate the intrinsic system, can be used to monitor danaparoid sodium; however, the target range for therapeutic anticoagulation is lower for patients receiving danaparoid sodium than for those receiving heparin.29 Lepirudin is also now being used in selected patients in the cardiopulmonary bypass setting.18,28,30-32 The whole blood level of lepirudin required for adequate anticoagulation during bypass surgery appears to be 3 to 4 µg/mL throughout the procedure.18,28 This higher value is in contrast to the plasma levels of approximately 0.6 µg/mL which are effective in patients with deep venous thrombosis.33 Because the high level required for cardiopulmonary bypass surgery cannot be accurately measured by the activated clotting time or aPTT, the ecarin clotting time has been developed and used successfully.18,28
The successful use of argatroban in a patient with HIT and thrombosis who required coronary stent implantation was first reported in 1996.34 A more recent report describes the use of argatroban in 50 patients who required percutaneous coronary revascularization and had a current or previous serologic or clinical diagnosis of HIT.35 They were excluded from treatment with argatroban if they were to undergo bypass surgery, had hepatic dysfunction, or were receiving a glycoprotein IIb/IIIa platelet receptor inhibitor. They received a bolus of 350 µg/kg followed by an infusion of 25 to 30 µg/kg/min. Additional drug was administered as needed to maintain the activated clotting time between 300 and 450 seconds. Adequate anticoagulation was obtained in all but one patient and procedural success was documented in 98%. Two of the 50 patients had complications, which included a retroperitoneal hematoma in one and an acute coronary closure that required bypass surgery in a second patient. Argatroban has received approval from the FDA for use in patients with active HIT or a history of HIT who are undergoing a percutaneous coronary intervention. For patients who have received argatroban in this setting, the drug has been continued at reduced doses for a mean of 2 days after the procedure, in part, to prevent thrombosis due to an ongoing procoagulant process.36 More experience is needed with the drug when used in combination with the inhibitors of the glycoprotein IIb/IIIa platelet receptors. Bivalirudin (Angiomax; The Medicines Company, Cambridge, MA), a 20-amino acid peptide modeled after native hirudin, is approved by the FDA for coronary angioplasty and could also be a very reasonable alternative to heparin in patients with HIT.37 Lepirudin has also been used successfully in patients with HIT requiring percutaneous coronary intervention.38 Doses sufficient to maintain the activated clotting time between 200 and 400 seconds have been used.
The duration of treatment for patients with HIT is not well defined. However, prospective studies suggest that the risk for thrombosis in a patient with HIT can persist up to at least 6 weeks; therefore, anticoagulation is recommended for at least 2 to 3 months. Warfarin should be initiated, while the patient is receiving danaparoid sodium or a thrombin-specific inhibitor, even if thrombosis is not apparent, because subclinical thrombosis can be present. In one study of 16 patients in whom HIT was diagnosed based on the time course of heparin and decrease in the platelet count, compression ultrasonography or venography of the lower limbs revealed evidence of deep venous thrombosis in 50% even though none showed clinical evidence of thrombosis.39 In a retrospective study of 62 patients who appeared to have only isolated thrombocytopenia as a manifestation of HIT and in whom heparin was discontinued and followed by no other treatment, the 30-day cumulative risk for thrombosis was 52.8%.40 For patients with HIT, discontinuation of heparin and initiation of warfarin alone has been associated with venous limb gangrene.41 The mechanism may be due to the transient initial decrease in protein C caused by warfarin combined with the ongoing thrombotic process. Warfarin has not been associated with gangrene or extension of thrombosis when initiated while a patient is receiving a thrombin-specific inhibitor or danaparoid sodium. Current recommendations are to initiate warfarin at low daily doses (5 mg or lower) while the patient is also receiving danaparoid sodium or a thrombin-specific inhibitor.42 The proper time for warfarin initiation is based on each individual case, but is probably best started when the platelet count is near or within the normal range. The international normalized ratio (INR) should be monitored daily when patients are receiving warfarin and argatroban. For patients who are receiving argatroban at a dose of 2 µg/kg/min or less, the argatroban can be discontinued when the INR is more than 4. The INR should then be repeated in 4 to 6 hours. For patients receiving lepirudin, the drug infusion rate should be lowered so the aPTT ratio is just above 1.5 before initiating warfarin. When an INR of 2 has been achieved, the drug should be stopped. These recommendations are guidelines and do not apply to every situation. They also emphasize the importance of waiting until patients have had an adequate therapeutic trial of thrombin-specific inhibitors before warfarin is initiated.
Patients should be told that they have developed antibodies induced by heparin, which places them at increased risk for thrombosis if heparin is needed again in the next 120 days and that alternative agents should be considered or they should be tested for antibodies before receiving heparin again. If they have a more remote history of HIT, they could probably receive heparin again if needed but other agents may be preferred. These recommendations are in evolution as more is learned about HIT. The most difficult decision is whether to use heparin in patients undergoing coronary artery bypass surgery. Although many patients are now undergoing surgery without the need for the cardiopulmonary bypass machine, the appropriate choice of an anticoagulant is still a critical issue.
One question concerns the appropriate dose of danaparoid sodium for prevention of thrombosis in a patient with HIT. In one study,43 patients with HIT who did not have thrombosis received danaparoid sodium, usually 750 U subcutaneously 2 or 3 times daily, or they received lepirudin at a prophylactic dose of 0.1 mg/kg/h intravenously (with the aPTT adjusted) until day 42 or discharge, whichever came first. In the patients receiving danaparoid sodium, the cumulative risk for thromboembolic events was higher than for the lepirudin-treated group (20% versus 6.3%; P = .087). This study shows that the ideal prophylactic dose for danaparoid sodium is not known, and prevention of thrombosis must be carefully balanced against increased risk for bleeding. The basic immunology of HIT is still not completely understood. Are all
patients who receive heparin equally at risk for this disorder? Some
studies have suggested that polymorphism for the Fc
This article was written by Dr Alving in her private capacity. The views expressed in this article do not necessarily represent the views of the National Institutes of Health, Department of Health and Human Services, or the United States.
Submitted April 9, 2002; accepted July 29, 2002.
Prepublished online as Blood First Edition Paper, August 15, 2002; DOI 10.1182/blood-2002-04-1089.
Reprints: Barbara Alving, Deputy Director, NHLBI, Room 5A47, Building 31, 31 Center Dr, Bethesda, MD 20892; e-mail: alvingb{at}nih.gov.
1. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol. 1999;36:17-21[Medline] [Order article via Infotrieve]. 2. Walenga JM, Jeske WP, Wood JJ, Ahman S, Lewis BE, Bakhos M. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol. 1999;36:22-28[Medline] [Order article via Infotrieve].
3.
Warkentin TE, Kelton JG.
Temporal aspects of heparin-induced thrombocytopenia.
N Engl J Med.
2001;344:1286-1292
4.
Warkentin TE, Sheppard JI, Horsewood P, et al.
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
Blood.
2000;96:1703-1708 5. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996;128:376-382[CrossRef][Medline] [Order article via Infotrieve].
6.
Bauer TL, Gowthami A, Konkle BA, et al.
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.
Circulation.
1997;95:1242-1246 7. Jackson MR, Gillespie DL, Chang AS, et al. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: a prospective study. J Vasc Surg. 1998;28:439-445[CrossRef][Medline] [Order article via Infotrieve].
8.
Warkentin TE, Kelton JG.
Delayed onset heparin-induced thrombocytopenia and thrombosis.
Ann Intern Med.
2001;135:502-506
9.
Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M.
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.
Blood.
2000;96:846-851 10. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655[Medline] [Order article via Infotrieve]. 11. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol. 1999;106:195-201[CrossRef][Medline] [Order article via Infotrieve].
12.
Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A.
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.
Blood.
2000;96:2373-2378
13.
Lewis BE, Wallis DE, Berkowitz SD, et al.
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Circulation.
2001;103:1838-1843 14. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost. 1992;18:135-149[Medline] [Order article via Infotrieve]. 15. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329[CrossRef][Medline] [Order article via Infotrieve].
16.
Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP Jr.
The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used.
Clin Chem.
1999;45:409-412 17. Reid TJ III, Alving BM. A quantitative thrombin time for determining levels of hirudin and Hirulog. Thromb Haemost. 1993;70:608-616[Medline] [Order article via Infotrieve].
18.
Pötzsch B, Madlener K, Seeling C, et al.
Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass
19.
Koster A, Loebe M, Hansen R, et al.
A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaption of the Ecarin clotting time to the act II device.
J Thorac Cardiovasc Surg.
2000;119:1278-1283 20. Danhof M, deBoer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Hemostasis. 1992;22:73-84.
21.
deValk HW, Banga JD, Wester JWJ, et al.
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism (a randomized controlled trial).
Ann Intern Med.
1995;123:1-9 22. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807[Medline] [Order article via Infotrieve].
23.
Tardy-Poncet B, Tardy B, Reynaud J, et al.
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Chest.
1999;115:1616-1620 24. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol. 1992;82:627-629[Medline] [Order article via Infotrieve]. 25. Vanholder RC, Camez AA, Veys NM, et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int. 1994;45:1754-1759[Medline] [Order article via Infotrieve]. 26. Fischer K-G, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kid Internat. 1999;56:S46-S50. 27. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Hemostasis. 1992;22:85-91. 28. Lathan P, Revelis A, Joshi GP, DiMaio JM, Jessen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology. 2000;92:263-266[CrossRef][Medline] [Order article via Infotrieve].
29.
Jackson MR, Danby CA, Alving BM.
Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.
Ann Thorac Surg.
1997;64:1815-1817 30. Potzsch B, Riess FC, Volpel H, Muller-Berghaus G, Greinacher. Recombinant hirudin as anticoagulant during open-heart surgery. Thromb Haemost. 1995;73:1456a. 31. Koster a, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology. 1998;89:777-780[CrossRef][Medline] [Order article via Infotrieve]. 32. Longrois D, de Maistre E, Bischoff N, Dopff C, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anesth. 2000;47:255-260[Medline] [Order article via Infotrieve]. 33. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost. 1993;3:386-388. 34. Lewis BE, Iaffaldano R, McKiernan TL, et al. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Catheter Cardiovasc Diag. 1996;38:206-209. 35. Matthai WH Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25:57-60[Medline] [Order article via Infotrieve]. 36. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Intervent. 2002;57:177-184[CrossRef][Medline] [Order article via Infotrieve].
37.
Bittl JA, Strony J, Brinker JA, et al.
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina.
N Engl J Med.
1995;333:764-769 38. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Catheter Cardiovasc Intervent. 2001;52:468-472[CrossRef][Medline] [Order article via Infotrieve]. 39. Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost. 1999;82:1199-1200[Medline] [Order article via Infotrieve]. 40. Warkentin T, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507[CrossRef][Medline] [Order article via Infotrieve].
41.
Warkentin TE, Elavathil LJ, Hayward CPM, et al.
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
Ann Intern Med.
1997;127:804-812 42. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:80S-94S. 43. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950-957[Medline] [Order article via Infotrieve].   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Introduction
Role of laboratory testing...
RII receptors on circulating platelets and
induces platelet activation, which promotes thrombin generation and
platelet aggregation. HIT is therefore a prothrombotic state that
frequently results in extension of existing thrombosis or the
development of new venous or arterial thrombosis. Although laboratory
tests are available to detect antibodies involved in HIT,
assessment of the whole blood Ecarin clotting time.
Thromb Haemost.
1997;77:920-925
